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

Insights In Healthcare

We are a fully independent, specialist healthcare company and our core business offers three specific services: Expert Panel and Advisory Board Services, Opinion Leader Identification and Advocacy Development and Strategic Healthcare Consulting.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to ensure patients gain access to life changing medicines and devices….

View Profile

Market access, Market research, Medical communications

Amiculum

AMICULUM works with the global healthcare industry to bring science to life across the product lifecycle from early opportunity assessment through to launch and beyond. By listening to the changing…

View Profile

Conference/meetings/events, Creative and design, Digital communications, Market access, Medical communications, Medical education, Training

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Advertising, Branding, Conference/meetings/events, Creative and design, Digital communications, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Sales, Training

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Market access, Regulatory affairs, Research and development

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs

Inizio

Welcome to Inizio. Your market-leading commercialization partner, providing tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access.

View Profile

Branding, Market access, Medical communications

Onyx Health

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national and international reach. As we understand the healthcare market and…

View Profile

Branding, Creative and design, Management consultancies, Market access, Market research, Media planning and buying, Medical communications, Medical education, Public relations

OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.

View Profile

Advertising, Branding, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Medical education, Patient support and adherence, Public relations, Training

Origins – The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value by involving patients throughout the entire product life cycle. We…

View Profile

Market access, Market research

Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups.

View Profile

Market access, Medical communications, Patient support and adherence

Red Thread Market Access Ltd

Blending brilliant writing with in-depth market access and reimbursement expertise

View Profile

Market access

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Clinical Research, Market access, Pharmacy

Visions4Health

Visions4Health are market access experts and your gateway to local adoption at pace. Leveraging our lived experience, understanding of national and local healthcare systems, and insights generated by our stakeholder…

View Profile

Health policy and government affairs, Market access, Market research

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.wpv-pagination-nav-links[data-toolset-views-view-pagination-block="33746bd812994fc2d16011719be6c6d7"] { text-align: left;justify-content: flex-start; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] { text-align: center; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link { background-color: rgba( 6, 147, 227, 1 );font-size: 16px;font-weight: bold; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link:hover { background-color: rgba( 142, 209, 252, 1 );border-radius: 5px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon { font-family: dashicons;margin-left: 8px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon::before { content: '\f465'; }   .tb-field[data-toolset-blocks-field="2352d76bb895ac4d7e6623b3996ba2ab"] { font-weight: bold; }  .tb-fields-and-text[data-toolset-blocks-fields-and-text="be25192e3b17b888e76f432f0e43e989"] { background-color: rgba( 142, 209, 252, 1 );padding-top: 5px;padding-bottom: 5px; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="03586fe69ea5b5174ebf265d564b8feb"] { padding: 0px 0px 5px 0px;margin-bottom: 10px;border-bottom: 2px solid rgba( 204, 203, 203, 1 ); } h3.tb-heading[data-toolset-blocks-heading="993a682c67afb3c5e9ef718484910c20"]  { font-size: 16px;color: rgba( 0, 51, 153, 1 );padding-bottom: 5px; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Company Details

Insights In Healthcare

2 Lordswood, Silchester, Reading, Berkshire, RG7 2PZ, United Kingdom

+44 (0)118 970 1204

Website

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Press Releases | June 24, 2026 | Genesis Research Group

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

Medscape Education to Showcase the Impact of Neurology CME at EAN 2026

Press Releases | June 23, 2026 | Medscape Education

Medscape Education, the leading global provider of continuing medical education (CME), has announced its agenda for the upcoming 12th Congress of the European Academy of Neurology (EAN) 2026 in Geneva,...

Designing Pharma Stands That People Actually Want to Step Onto

Press Releases | June 18, 2026 | Apex Events and Exhibitions

Exhibition halls are busy environments where delegates move quickly, often with limited time. For pharmaceutical companies, this presents a challenge: how do you create a stand that invites meaningful engagement...

Live Webinar | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

White Papers and Resources | June 18, 2026 | Inizio

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

The solution: Good localisation doesn’t feel translated

White Papers and Resources | June 18, 2026 | Cuttsy + Cuttsy

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Good Patient Partnership Guide 2026: Patient Journey Mapping with the Patient Community

White Papers and Resources | June 18, 2026 | Precision AQ

Patient insight gathering and journey mapping can inform and enhance decision making and initiatives across life sciences. The Good Patient Partnership Guide 2026 brings together practical guidance, real world examples...

Healthcare information is becoming easier to access. Trust isn’t.

White Papers and Resources | June 17, 2026 | Cuttsy + Cuttsy

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

White Papers and Resources | June 17, 2026 | Cuttsy + Cuttsy

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.

J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment

Press Releases | June 17, 2026 | Uniphar

Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology...

Medscape Education Recognized With 2 Spring 2026 Digital Health Awards for Excellence in Clinical Education

Press Releases | June 16, 2026 | Medscape Education

Medscape Education has been recognized with 2 prestigious accolades at the Spring 2026 Digital Health Awards. The premier digital education platform earned a Gold Award for its PIONEER initiative in...